

***h*TERC Gene Amplification Detection by FISH in Acute Myeloid Leukemia Patients**

Thesis

Submitted for Partial Fulfillment of M.Sc. Degree
In Clinical and Chemical Pathology

By

Islam Mohamed Hanafi Fadel

M.B., B.Ch
Menufia University

Supervised by

Professor \ Iman Mohamed Amin Omar

Professor of Clinical and Chemical Pathology
Faculty of Medicine - Ain Shams University

Professor \ Daliah Ahmed El Sewefy

Professor of Clinical and Chemical Pathology
Faculty of Medicine - Ain Shams University

Professor \ Nivine Abd El Rahman Helmy

Professor of Human Cytogenetics
Human Cytogenetics Department
Human Genetics and Genome Research Division
National Research Center

Faculty of Medicine
Ain Shams University

2011

الكشف عن تضاعف جين ال *hTERT* باستخدام تقنية التهجين الموضعي الفلوريسينتي في مرضى الابيضاض النقي الحاد

رسالة
توطئة للحصول علي درجة الماجستير
في الباثولوجيا الإكلينيكية و الكيميائية

مقدمة من
الطبيب / إسلام محمد حنفي فاضل
بكالوريوس الطب والجراحة العامة
كلية الطب - جامعة المنوفية

تحت إشراف

الاستاذ الدكتور/ إيمان محمد أمين عمر
أستاذ الباثولوجيا الإكلينيكية والكيميائية
كلية الطب - جامعة عين شمس

الاستاذ الدكتور/ داليه أحمد السويدي
أستاذ الباثولوجيا الإكلينيكية والكيميائية
كلية الطب - جامعة عين شمس

الاستاذ الدكتور/ نيفين عبدالرحمن حلمي
أستاذ الوراثة البشرية الخلوية
قسم الوراثة البشرية الخلوية
شعبة الوراثة البشرية و أبحاث الجينوم
المركز القومي للبحوث

كلية الطب
جامعة عين شمس

2011

SUMMARY AND CONCLUSION

Acute myeloid leukemia describes a heterogenous group of hematological disorders characterized by a block in the terminal differentiation of a particular hematopoietic cell lineage. Cytogenetic and molecular assays have allowed patients' follow up aiming for detection of minimal residual disease, prediction of patients' outcome, in addition to providing the rationale for designing novel molecular-targeted therapeutic strategies.

Human telomerase RNA component (hTERC), encoded by the hTERC gene is frequently amplified in human tumors, which indicates that the hTERC gene may be a target for amplification during the transformation of human malignancies including hematological malignancies. This genetic event has implications in diagnosis, prognosis and therapeutics of cancer.

In this regard, this study aimed to detect hTERC gene amplification in AML patients by FISH analysis and its relation to the standard prognostic factors.

In the current work, BM or PB samples were obtained from 21 adult AML patients, presented at the Hematology/Oncology Unit, Ain Shams University Hospitals. The patients were further divided into two groups; group I (12 patients) containing newly diagnosed AML patients and a relapsed case and group II (8 patients) containing patients taken at 28th day of chemotherapy.

All patients were subjected to complete history, thorough clinical examination and laboratory investigations including: complete hemogram, bone marrow aspiration with examination of Leishman-stained peripheral blood and bone marrow smears, immunophenotyping, karyotyping and detection of hTERC gene amplification using FISH technique.

Acknowledgement

*First of all, great thanks to **ALLAH** who is most merciful, for all the countless gifts I have been offered.*

*I would like to express my endless gratitude and appreciation to **Professor. Iman Mohamed Amin Omar** Professor of Clinical and Chemical Pathology, Ain Shams University, for her continuous guidance, valuable suggestions and keen supervision throughout the work.*

*I would like to express my sincere gratitude and deepest appreciation to **Professor. Nivine Abd El Rahman Helmy**, Professor of Human Genetics, National Research Center, for her instructive supervision & encouragement, remarkable guidance, great concern, scientific and personal support throughout the course of this work.*

*My endless thanks to **Professor. Daliah El Sweify**, Professor of Clinical and Chemical Pathology, Ain Shams University, for her valuable instructions, generous help, unlimited support and effort to get best out of this work.*

*Indeed, words do fail me when I come to express my profound gratitude and deep appreciation to **Doctor. Maha Mohamed Eid** for her everlasting support, honest encouragement and for offering me much of her time and effort.*

*Many thanks to **Doctor. Danzhou Yang**, Associate Professor of Medicinal Chemistry, University of Arizona for helping me understanding the telomere model and for his kind supplementation of books.*

*Last, but not least, I would like to thank **my family** for their actual help and support received in many ways.*

Islam Fadel

List of Contents

	Page
✂ List of Abbreviations	i
✂ List of Tables	vi
✂ List of Figures	viii
✂ Introduction.....	1
✂ Aim of the Work.....	3
✂ Review of Literature	4
<u>Chapter 1: TELOMERE AND TELOMERASE.....</u>	4
I.TELOMERE.....	4
II.TELOMERASE.....	9
III. REGULATION OF TELOMERASE	
ACTIVITY.....	14
IV. CLINICOPATHOLOGICAL IMPORTANCE OF	
TELOMERASE.....	21
V. TELOMERASE IN AML.....	29
<u>Chapter 2: ACUTE MYELOID LEUKEMIA.....</u>	33
I. EPIDEMIOLOGY.....	33
II. MOLECULAR PATHOGENESIS.....	35
III. CLASSIFICATION.....	40
IV. DIAGNOSIS.....	44
V. TREATMENT.....	69
VI. PROGNOSIS.....	73

✎ Subjects and Methods.....	81
✎ Results.....	95
✎ Discussion	120
✎ Summary and Conclusion.....	126
✎ Recommendations	129
✎ References	130
✎ Arabic Summary	148

List of Abbreviations

A	Alpha
B	Beta
χ^2	Chi-square
-	Monosomy
+	Trisomy
°C	Degrees centigrade
μ	Micro
ALL	Acute lymphoblastic leukemia
ALT	Alternative Lengthening of Telomeres
AML	Acute myeloid leukemia
AMML	Acute myelomonocytic leukemia
AP	Acid Phosphatase
AP1	Activator protein 1
APL	Acute promyelocytic leukemia
ATRA	All-trans retinoic acid
BAALC	Brain and acute leukemia, cytoplasmic
BM	Bone Marrow
bp	Base Pair
c	Cytoplasmic
CBF β	Core binding factor β
CCA	Conventional Cytogenetic Analysis
CD	Cluster of differentiation
cDNA	Complementary DNA
CEBPA	CCAAT/enhancer-binding protein alpha
CGH	Comparative Genomic Hybridization
CIR	crude incidence rate of cancer
c-KIT	Proto-oncogene tyrosine-protein kinase
CML	Chronic myeloid leukemia
c-myc	Cellular myelocytomatosis
CN	Cytogenetically normal
CNS	Central nervous system
CpG	Cytosine followed by Guanine on the same strand
CR	Clinical remission
CRD	Complete remission duration
C-terminal	Carboxyl terminal
DAPI II	4',6-diamidino-2-phenylindole

Del	Deletion
D-FISH	Double fusion Fluorescence In Situ Hybridization
DFS	Disease free survival
DIC	Disseminated intravascular coagulopathy
DKC	dyskeratosis congenita
DKC1	dyskeratosis congenita gene 1
DNA	Deoxyribonucleic acid
DSB	Double strand breaks
DW	Distilled water
EM	Electron microscopy
EFS	Event free survival
ETS	E-twenty six family of transcription factors
ERG	ETS-related gene
FAB	French-American-British
FdU	Fluorodeoxyuridine
FISH	Fluorescence In Situ Hybridization
FLT3	FMS-like tyrosine kinase 3
FLT3-TKD	Tyrosine kinase domain of FLT3
G	Guanine
gm	Gram
G1	G1 Phase in cell cycle the Pre-synthetic phase
G-banding	Giemsa banding
GEP	Gene expression profiling
G-quadruplex	Guanine-quadruplex
G-rich	Guanine -rich
H	Histone
H/ACA	RNA-protein complex component
H2AX	a phosphorylated variant of histone 2A
H3	Histone 3
H4	Histone 4
HB	Hemoglobin
HCL	Hydrochloric acid
HEST1A	Human ever shorter telomeres-1
HiDAC	High-dose cytarabine
HIF-1	hypoxia-inducible factor 1
HLA	Human leucocyte antigene
hMSC	Human mesenchymal stem cells
hnRNP A1	Heterogenous nuclear ribonucleoprotein A1

hnRNP C	Heterogenous nuclear ribonucleoprotein C
hnRNP D	Heterogenous nuclear ribonucleoprotein D
Hox	Homeobox proteins
HR	Homologous recombination
HRE	Hypoxia response element
HSCT	Hematopoietic stem-cell transplantation
hsp 90	Heat-shock protein 90
HSP70-1	Heat-shock-70 kDa protein
HSP90A	Heat-shock-90 kDa protein 1, alfa
hSTAU	Human staufen homolog; double-stranded RNA-binding protein
hTERC	Human telomerase RNA component
hTERT	Telomerase reverse transcriptase
hTP1	Human telomerase-associated protein 1
Inv	Invesion
ITD	Internal tandem duplication
kb	Kilo-base
kDa	Kilo Dalton
K-EDTA	K-ethylene diamine tetraacetic acid
LDH	Lactate dehydrogenase
LN	lymph node
LSP	Locus specific probe
M1,2	Mortality phase 1, 2
MAPK	mitogen-activated protein kinase
Mb	Mega base
MDM2	Murine double minute
MDR	Multidrug resistance
MDS	Myelodysplastic syndrome
MEKK1	Mitogen-activated protein kinase kinase kinase 1
MFC	Multiparameter Flow Cytometry
MLL	Mixed lineage leukemia lymphoma gene
mm ³	Cubic millimeter
MPO	Myeloperoxidase
MRD	Minimal residual disease
mRNA	Massenger ribonucleic acid
MW	Molecular weight
MYH11	Myosin heavy chain 11
n	Repeats

NaF	Sodium floride
NF-Y	Nuclear Factor Y
NHEJ	Non homologous end joining
NOLA1	Nucleolar protein family A, member 1
NOLA2	Nucleolar protein family A, member 2
NOLA3	Nucleolar protein family A, member 3
NP40	Tergitol-type NP-40, (nonyl phenoxypolyethoxylethanol)
NPM	Nucleuphosmin
NPMc+	Nucleuphosmin (cytoplasmic form)
nt	nucleotide
N-terminal	Amino terminal
OS	Overall survival
P23	Unactive progesterone receptor 23 kD
P53	Tumor protein 53
PAS	Periodic Acid Schiff's
PB	Peripheral blood
PCR	Polymerase chain reaction
PI 3-kinase	phosphatidylinositol 3-kinase
Pin2	NIMA-interacting protein 2. A splicing isoform from TRF1 gene
PinX1	TRF1/Pin2-interacting protein 1
PLT	Platelet
PML-RARA	Promyelocytic leukemia/ Retinoic acid receptor alpha
PMT	Photo-multiplicator
POT1	Protection of telomeres 1
pRb	Retinoblastoma protein
PTD	Partial tandem duplication
PTH	Parathyroid hormone
Rap1	Repressor activator protein 1
RAR	retinoic acid receptor
RNA	Ribonucleic acid
rpm	Revolution per minute
RQ-PCR	Real time quantitative PCR
RT-PCR	Reverse transcription-polymerase chain reaction
SBB	Sudan Black B
scaRNA	Small Cajal body-specific RNAs
SD	Standard deviation

SnoRNA	Small nucleolar RNA
Sp1	Specificity Protein 1
Sp3	Specificity Protein 3
SSC	Standard saline citrate
t	Translocation
T'' loop	Telomere loop
TCR	T cell Receptor
TdT	Terminal deoxynucleotidyl transferase.
TIN2	TRF1-interacting protein 2
TLC	Total leucocytic count
TPP1	Tripeptidyl peptidase 1
TRAP	Telomere repeat amplification protocol
TRF1	Telomere repeat binding factor 1
TRF2	Telomere repeat binding factor2
WBCs	White blood cells
WHO	World Health Organization
yr	Year

LIST OF TABLES

Table No.	Table title	Page No.
1	Function of Telomere Associated Proteins	6
2	Telomerase Associated Proteins	10
3	Conditions Predisposing to Development of AML	36
4	FAB Classification of Acute Myeloid Leukemia	41
5	Cytochemical Stains in AML	49
6	Immunophenotyping Panels Used to Diagnose Different Subtypes of Acute Leukemia	54
7	Shows Immunophenotype of Different Subtypes of AML	54
8	Expression of Cell-Surface and Cytoplasmic Markers for the Diagnosis of Acute Myeloid Leukemia and Mixed Phenotype Acute Leukemia	55
9	Methods for the Detection of MRD in AML	68
10	Novel agents potentially useful for acute myeloid leukemia	72
11	Summarizes the Most Important Prognostic Factors in AML	73
12	Classification of AML Patient According to Cytogenetics	75
13	Probe Signal Interpretation	93
14	Clinical Data of Studied AML Patients	105
15	Laboratory Data of Studied AML Patients	106

Table No.	Table title	Page No.
16	Immunophenotyping and FAB Classification of Studied AML Patients.	107
17	Descriptive statistics of karyotyping, prognosis, FISH analysis and outcome for all studied patients	108
18	Different Patterns of Karyotyping Detected Among Studied AML Patients	109
19	Comparison between “Group I” group and “Group II” group as regard clinical data:	110
20	Comparison between “Group I” group and “Group II” group as regard laboratory data	111
21	Statistical Comparison Between “Good Outcome” and “Poor Outcome” Patients Regarding All Studied Parameters	112
22	Pearson’s correlation between number of cells with amplification and other studied parameters	113
23	Statistical Comparison Between Patients with “< 20% of Amplification” and Patients with “≥ 20% of Amplification” Regarding All Studied Parameters.	114

LIST OF FIGURES

Table No.	Figure Title	Page No.
1	Telomere Model	5
2	A schematic showing the end replication problem	9
3	structure of hTERT gene, mRNA, polypeptide chain	11
4	Molecular structure of hTERC	13
5	Showing Transcriptional regulation of the hTERC core promoter	15
6	Showing regulation of telomerase genes at chromatin levels	19
7	Telomerase bypassing M1 senescence and M2Crises leading to cell immortality	25
8	DNA damage signal from too short telomeres	26
9	Role of telomeres and cell cycle check points in cancer	27
10	Age distribution of AML in the population of Wales: a population study	34
11	The interplay of different molecular alterations in the development of AML	37
12	Myeloblast showing fine chromatin, basophilic cytoplasm, 1-5 nucleoli and Auer rods may be seen	47
13	Left: myeloblasts with typical eccentric nuclei. Auer rods visible. Right: Sudan black B staining and Auer rods	49

Table No.	Figure Title	Page No.
14	Typical myeloblasts with eccentric nuclei and maturing dysplastic granulocytes at all stages of development.	50
15	Sudan black B positivity in blasts, stronger in dysplastic metamyelocytes. Inset: Chloroacetate in maturing granulocytes	50
16	Hypergranular promyelocytes (right). Variable granule content and multiple Auer rods visible (left).	50
17	Sudan black B stain. Typical heavy cytoplasmic positivity.	50
18	Promyelocyte chloroacetate esterase positivity (blue). Inset: atypical ANAE positivity seen in 1% of M3 cases.	51
19	Typical bilobed nuclei and basophilic cytoplasm packed with granules too small to resolve by light microscopy, but which give typical M3v cytochemical reactions.	51
20	Mixed population of myeloblasts and monoblasts. Inset: chloroacetate esterase positive granules (blue), ANAE-positive monocytes (green/brown).	51
21	Left: large monoblasts with central nuclei and abundant cytoplasm. Right: monoblast ANAE positivity (brown), and one blue chloroacetate esterase positive myelocyte	51
22	Marked dyserythropoiesis (>50% of cells), with dysplastic granulocytes.	52
23	Left: giant multinucleate late normoblasts. Right: PAS stain; granular in proerythroblasts, homogeneous in normoblasts	52
24	Megakaryoblasts / micro- megakaryocytes in bone marrow aspirate.	52